Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 252

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 252
---
 ELYXYB. Our managed healthcare account executives will negotiate contracts with key payer and 
 pharmacy stakeholders to achieve uptake to key formularies.                                                     |

167

| • |     | Commercialize and successfully continue launch of                                                                                                                                                                                                                                                                                                                               
 GLOPERBA® for gout in the U.S. We will utilize our current commercial infrastructure comprised of our sales, marketing, and managed health care functions to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe colchicine for gout, allowing for 
 efficient dual promotion of GLOPERBA and ZTlido. The principal elements of the GLOPERBA strategy are as follows:                                                                                                                                                                                                                                                                |

| • |     | Educate the market on the need for and value of simplified and precise colchicine dose adjustments to allow                                                                                                                                       
 individualized, patient-by-patient therapy. Scilex will leverage its in-person sales forces, medical affairs teams, and                                                                                                                           
 omni-channel HCP engagement campaigns to drive awareness of GLOPERBA’s features and benefits. In addition, target providers, rheumatologists and primary care physicians treating various comorbidities, will be provided with tools to help them 
 identify and prescribe GLOPERBA to appropriate patients.                                                                                                                                                                                          |

| • |     | Increase access to GLOPERBA for subsets of patients in prophylactic treatment of gout, specifically those with                                                                   
 comorbidities and GI intolerance. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy customers to achieve uptake of key formularies. |

| • |     | Develop and commercialize SEMDEXA as a novel epidural injection for the first approved treatment of                                                                                                                                                      
 sciatica. We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used off-label. Many of these products contain potentially                                             
 neurotoxic preservatives and particulates, and are administered over 12 million times annually despite a warning on the label of serious neurologic complications, including loss of vision, stroke, paralysis and death. These products carry           
 warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation from the FDA and, if approved, could become the first                                         
 FDA-approved epidural steroid product with